---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-24-000019"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T08:02:55.771087+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Prothena licenses PRX019 to BMS for $80M upfront; milestones up to $617.5M

## Summary
- Upfront payment of $80 million from BMS; eligible for additional development and regulatory milestones up to $242.5M.
- Sales milestones up to $375M upon achieving certain annual net sales thresholds.
- Tiered royalties on worldwide net sales ranging from high single-digit to high teen percentages.
- Prothena obligated to run Phase 1 for PRX019; BMS may elect to take over the trial.
- Research term under Master Collaboration Agreement expired on May 24, 2024.

## SEC filing metadata
- accession: 0001559053-24-000019
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905324000019/0001559053-24-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905324000019/prta-20240524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-24-000019
- JSON: https://secwatch.observer/filing/0001559053-24-000019.json
- Plain text: https://secwatch.observer/filing/0001559053-24-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.